By: Crystal Carter
A research tool developed at the Texas A&M Institute of Biosciences and Technology is reshaping how scientists investigate inflammation and its role in cardiovascular disease. The RhoE knockout cell line acts like a high-resolution research lens, illuminating how inflammatory pathways are activated, suppressed, or rerouted in the absence of a key regulatory protein. Inflammation is essential for healing, yet when it becomes prolonged or dysregulated, it can worsen tissue damage and hinder recovery.
The CRISPR-modified RhoE knockout system was developed by Jiang Chang, MD, PhD, professor at the Texas A&M University Institute of Biosciences and Technology, deputy director of the Center for Genomic and Precision Medicine, and Chancellor’s Edge Fellow, along with co-inventor Weijia Luo, PhD, research assistant professor at the Institute of Biosciences and Technology.
A step in bringing this technology to the global research community is the licensing agreement between The Texas A&M University System and Applied Biological Materials, Inc. (ABM), a biotechnology company known for its agility in developing and commercializing cutting-edge research tools. Through this agreement, ABM will help introduce the technology into the broader scientific ecosystem, accelerating research into therapeutic discovery, biomarker development, and the molecular mechanisms of inflammation.
Heart disease remains the leading cause of death globally, and inflammation is a central factor in many of the world’s most challenging medical conditions. By supplying researchers with a more precise way to study these processes, the RhoE knockout technology helps accelerate the development of targeted therapies and predictive biomarkers. Contact Stewart Davis, Assistant Director, Licensing, for more information. Learn more about our available technologies on our website.
